TY - JOUR
T1 - Treatment burden, healthcare experiences, and health-related quality of life among youth with chronic kidney disease treated for hypertension
AU - Botdorf, Morgan
AU - Marchesani, Nicole
AU - Ruebner, Rebecca
AU - Di Cocco, Elana
AU - Davies, Amy J.Goodwin
AU - Hammond, India Shepherd
AU - Musante, Jordan
AU - Jovanovska, Aneta
AU - Levondosky, Mark
AU - Levondosky, Rebecca
AU - Besser, Victoria H.
AU - Claes, Donna J.
AU - Dawson, Anne E.
AU - Dixon, Bradley P.
AU - Gluck, Caroline
AU - Halbach, Susan M.
AU - Harshman, Lyndsay
AU - Katsoufis, Chryso
AU - Kula, Alexander J.
AU - Moon, Young Hyun
AU - Patterson, Larry
AU - Salmon, Eloise
AU - Talley, Elizabeth M.
AU - Denburg, Michelle R.
AU - Forrest, Christopher B.
N1 - © 2026. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2026/9/24
Y1 - 2026/9/24
N2 - BACKGROUND: Controlling blood pressure (BP) is essential for slowing chronic kidney disease (CKD) progression. This study examined the associations between treatment burden, assessed by antihypertensive medication use, and health-related quality of life (HRQoL) in youth with CKD and hypertension. METHODS: Youth (aged 8 to 21 years) were identified through electronic health records from 15 institutions. Youth and caregivers completed an online questionnaire assessing healthcare experiences, medication use, physical symptoms, and BP monitoring. HRQoL and related well-being domains (fatigue, anxiety, sleep disturbance, global health, and life satisfaction) were assessed using PROMIS® measures. Analyses focused on youth-reported outcomes. Linear regression estimated associations between antihypertensive medication use and HRQoL outcomes, and scores were compared to the general population. RESULTS: The study included 395 youth (Mage = 16.8 years, 54% female) and 238 caregivers. Over 95% of caregivers reported generally positive healthcare experiences. Most youth (92%) reported at least one of the physical symptoms asssessed (median [IQR] = 5 [3, 8] symptoms). Twenty-one percent took no antihypertensive medications, 56% took one, and 23% took multiple. Use of multiple medications was associated with slightly lower global health (B = - 2.6; 95% CI: - 4.9, - 0.3) after adjustment for CKD stage. No associations were observed for other HRQoL domains. Overall, youth reported lower QoL than the general population, with the greatest impairments observed in global health and fatigue. DISCUSSION: Youth with CKD and hypertension reported generally positive healthcare experiences, and antihypertensive medication use, one component of treatment burden, showed minimal association with HRQoL. Despite modest effects, continued attention to HRQoL remains an important aspect of care for youth with CKD and hypertension.
AB - BACKGROUND: Controlling blood pressure (BP) is essential for slowing chronic kidney disease (CKD) progression. This study examined the associations between treatment burden, assessed by antihypertensive medication use, and health-related quality of life (HRQoL) in youth with CKD and hypertension. METHODS: Youth (aged 8 to 21 years) were identified through electronic health records from 15 institutions. Youth and caregivers completed an online questionnaire assessing healthcare experiences, medication use, physical symptoms, and BP monitoring. HRQoL and related well-being domains (fatigue, anxiety, sleep disturbance, global health, and life satisfaction) were assessed using PROMIS® measures. Analyses focused on youth-reported outcomes. Linear regression estimated associations between antihypertensive medication use and HRQoL outcomes, and scores were compared to the general population. RESULTS: The study included 395 youth (Mage = 16.8 years, 54% female) and 238 caregivers. Over 95% of caregivers reported generally positive healthcare experiences. Most youth (92%) reported at least one of the physical symptoms asssessed (median [IQR] = 5 [3, 8] symptoms). Twenty-one percent took no antihypertensive medications, 56% took one, and 23% took multiple. Use of multiple medications was associated with slightly lower global health (B = - 2.6; 95% CI: - 4.9, - 0.3) after adjustment for CKD stage. No associations were observed for other HRQoL domains. Overall, youth reported lower QoL than the general population, with the greatest impairments observed in global health and fatigue. DISCUSSION: Youth with CKD and hypertension reported generally positive healthcare experiences, and antihypertensive medication use, one component of treatment burden, showed minimal association with HRQoL. Despite modest effects, continued attention to HRQoL remains an important aspect of care for youth with CKD and hypertension.
KW - Ambulatory blood pressure monitoring
KW - Chronic kidney disease
KW - Hypertension
KW - Patient reported outcomes
KW - Pediatrics
KW - Quality of life
KW - Antihypertensive Agents/therapeutic use
KW - Humans
KW - Cost of Illness
KW - Male
KW - Quality of Life/psychology
KW - Caregivers/psychology
KW - Renal Insufficiency, Chronic/psychology
KW - Young Adult
KW - Adolescent
KW - Female
KW - Surveys and Questionnaires
KW - Child
KW - Hypertension/drug therapy
UR - https://www.scopus.com/pages/publications/105051677856
U2 - 10.1007/s11136-026-04401-x
DO - 10.1007/s11136-026-04401-x
M3 - Article
C2 - 42782549
AN - SCOPUS:105051677856
SN - 0962-9343
VL - 35
JO - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
JF - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
IS - 10
M1 - 292
ER -